Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Open Access
- 1 July 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (7), 3122-3125
- https://doi.org/10.1128/aac.00361-09
Abstract
We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.This publication has 12 references indexed in Scilit:
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe ZygomycosisAntimicrobial Agents and Chemotherapy, 2008
- The iron chelator deferasirox protects mice from mucormycosis through iron starvationJCI Insight, 2007
- A higher-level phylogenetic classification of the FungiMycological Research, 2007
- Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral MucormycosisAntimicrobial Agents and Chemotherapy, 2006
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and ManagementClinical Microbiology Reviews, 2005
- Iron-chelating therapy with the new oral agent ICL670 (Exjade®)Best Practice & Research Clinical Haematology, 2005
- The Effect of Deferoxamine on Different ZygomycetesThe Journal of Infectious Diseases, 1994
- Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.JCI Insight, 1993